[Immunophenotype of lymphocytes of patients with malignant melanoma and its dynamics during immunotherapy with interleukin-2].
A Mab set was used to study immunological phenotype of lymphocytes of five patients bearing stage IV malignant melanoma and its changes developing in the course of interleukin-2 (Euro cetus) immunotherapy. Patients were shown to have lowered counts of T cells (mainly due to T-helper/inducers), B cells and lymphocytes expressing adhesion and activation molecules as well as abnormal immunoregulatory cell ratio. Two patients receiving interleukin-2 achieved a response. Follow-up of antigen expression revealed a rise in natural killer and immunoregulatory T lymphocyte levels in the responders whereas activation antigens and B cell levels were increased in all the patients.
Kadagidze
Z G
ZG
Iavorskiĭ
V V
VV
Baryshnikov
A Iu
AIu
Solov'eva
E A
EA
Savel'eva
E V
EV
Cheremushkin
E A
EA
Korotkova
O V
OV
D000911:Antibodies, Monoclonal; D001402:B-Lymphocytes / Q000276:immunology; D003606:Dacarbazine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D016131:Lymphocyte Subsets / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology*; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D003606:Dacarbazine
Immunologicheskiĭ fenotip limfotsitov bol'nykh so zlokachestvennoĭ melanomoĭ i ego dinamika v protsesse immunoterapii interleĭkinom-2.